Blog - UPRA | Ukrainian Psychedelic Research Association | психоделічно асистована терапія | ПАТ | Ukraine

Skip to main content

2C-B: The Forgotten Psychedelic That Could Be a Game-Changer

14 January 2025 | Переглянуто: 3919

The topic of psychedelics in the structure of the educational process

08 January 2025 | Переглянуто: 370

Magic mushrooms and personal safety: scientific protocols for the use of psilocybin-containing substances

24 November 2024 | Переглянуто: 1774

Legal issues of introducing ketamine-assisted therapy in Ukraine

22 November 2024 | Переглянуто: 475

MDMA as medicine after the Israeli-Palestinian war

20 November 2024 | Переглянуто: 691

From Drugs to Medicine: How the U.S. Changed Its Perception of Psychedelics Over Half a Century

30 August 2024 | Переглянуто: 625

Psychedelic-assisted therapy

21 August 2024 | Переглянуто: 615

FDA Rejects Lykos’ Drug Application and Requests an Additional Phase 3 Clinical Trial

14 August 2024 | Переглянуто: 307

Post-traumatic stress disorder (PTSD)

11 August 2024 | Переглянуто: 166

Why Did the FDA's Advisory Committee Recommend Rejecting MDMA as a PTSD Treatment and What Does This Mean for Ukraine?

04 July 2024 | Переглянуто: 1553

UPRA manifesto: what scientific evidence we rely on and what we strive for

28 April 2023 | Переглянуто: 547

Prince Harry's psychedelic coming out

15 January 2023 | Переглянуто: 472

UPRA Breakthrough: The Association's Growth in 2022

30 December 2022 | Переглянуто: 1274

Meet UPRA: Elizabeth Ames

28 September 2022 | Переглянуто: 195

Meet UPRA: Oleg Orlov

25 August 2022 | Переглянуто: 322